"Our bacteriophage-based therapy represents a natural and effective alternative to the overuse of antibiotics in agriculture, which may be contributing to the alarming rise in antibiotic-resistant bacterial infections in humans," said EpiBiome's CEO and Co-Founder, Dr. Nick Conley. "We are honored to be recognized by such a renowned organization for our efforts – one that shares the same values and vision of transforming the world through innovation."
In addition to being named a Buzz of BIO winner, EpiBiome will have an active presence at the convention, which runs June 6-9, where Dr. Conley is scheduled to:
- Present in the "Global Workshop for Novel Anti-Infectives" from 11 a.m. to 12:30 p.m. PST on June 6 in South 105
- Give an honorary Buzz of BIO company presentation on June 6 at 2:30 p.m. in Theater 3
- Moderate the panel "Living Therapeutics: Harnessing the Microbiome" from 10:30 to 11:30 a.m. on June 9 in West 3001
- Participate in the BIO partnering sessions from June 6-8
"I'm pleased to see Nick and the entire EpiBiome team so involved in BIO," said Dr. Thomas Shryock, Chief Scientific Officer at Antimicrobial Consultants, LLC, who serves on the EpiBiome scientific advisory board and is a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. "The recognition they've achieved from the organization speaks volumes to the company's innovative solution in combating antibiotic resistance through reduction of antibiotic use in agriculture. I look forward to seeing their continued progress and the impact bacteriophage-based therapy will have on both animal and human health."
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech. It offers key networking and partnering opportunities and provides insights and inspiration on major trends affecting both biotechnology and life sciences. The convention draws leaders from all facets of the aforementioned communities, including investments, policy, state initiatives, economic development and the international marketplace.
EpiBiome is a venture-backed precision microbiome engineering company working to curb the growing threat of multi-drug-resistant bacteria by eliminating the use of shared-class antibiotics, those shared between humans and animals, from agriculture.
The company's management team consists of Nick Conley, PhD (Chief Executive Officer and Co-Founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-Founder), Christina Tsai, PhD (Chief Science Officer & Co-Founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer). EpiBiome is located at 201 Gateway Blvd., South San Francisco, California 94080. For more information, visit http://www.epibiome.com.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Logo - http://photos.prnewswire.com/prnh/20160203/329429LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epibiome-named-buzz-of-bio-winner-for-the-2016-bio-international-convention-300278956.html